预约演示
更新于：2026-07-21
Camrelizumab
卡瑞利珠单抗
更新于：2026-07-21
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-05-29), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、附条件批准 (中国)、突破性疗法 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 9905931L
来源: *****
Sequence Code 13337117H
来源: *****
关联
963
项与 卡瑞利珠单抗 相关的临床试验NCT07662681
A Prospective, Multi-Cohort Study of Camrelizumab in Combination With Famitinib for the Treatment of Patients With Rare Head and Neck Malignancies
This is a prospective, multicenter, multi-cohort, Phase II clinical trial enrolling patients with unresectable, recurrent, or metastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or salivary gland malignancies (excluding adenoid cystic carcinoma) who have not previously received PD-1 inhibitor therapy. The planned sample size is 10 subjects per cohort, for a total of 40 subjects. Investigators may adjust the cohort sample sizes based on actual enrollment. Potentially eligible subjects will be screened within 4 weeks prior to the first dose to assess their eligibility for study entry. Subjects confirmed by the investigator to meet all inclusion criteria and none of the exclusion criteria will receive the investigational medicinal products as per the study design and undergo efficacy and safety assessments. This trial will consist of three periods: Screening/Baseline Period, Treatment Period, and Follow-up Period. The study procedures include: Screening Period: From the signing of the informed consent form up to 28 days prior to the first dose; Treatment Period: Treatment discontinuation is defined as the cessation of treatment for any reason, such as disease progression or intolerance, or premature withdrawal for any reason; Follow-up Period: Following the subject's last dose, safety follow-up will be initiated to monitor the resolution of adverse events. The first safety follow-up visit will occur 30 ± 7 days after the last study dose (calculated based on the later date of 30 days post the last dose of either camrelizumab or famitinib). Subjects are required to return to the study center for this safety follow-up, regardless of whether they have initiated new antineoplastic therapy. The subsequent two safety visits (60 ± 7 days and 90 ± 7 days after the last dose) may be conducted via telephone. After study discontinuation, survival follow-up will be conducted every 3 months to monitor survival status and subsequent antineoplastic treatments. The dosing regimen is as follows: camrelizumab 200 mg, IV, on Day 1, Q3W; famitinib 10 mg, PO, QD, Q3W, with 21 days constituting one treatment cycle. Study drugs should be administered at approximately the same time each day. If a patient vomits or misses a dose, no replacement dose should be taken on that day, and the next scheduled dose should be taken as usual. Subjects will continue treatment with camrelizumab and famitinib until discontinuation criteria are met. Clinical tumor imaging assessments will be performed every 2 cycles according to RECIST v1.1 (Appendix IV). Additionally, on Day 1 of each treatment cycle, clinically required assessments must be completed, including vital signs, physical examination, complete blood count, urinalysis, fecal occult blood test, hepatic and renal function tests, serum electrolytes, serum proteins, coagulation profile, serum tumor markers, thyroid function, electrocardiogram (ECG), and ECOG performance status score (specific assessments for each visit are detailed in the Schedule of Assessments). Hepatitis virus carriers will also require viral load monitoring every 2 to 4 treatment cycles.
开始日期2026-07-01 |
申办/合作机构 |
NCT07653451
Precision Medicine Strategies for Advanced Esophageal Cancer Refractory to Immune Checkpoint Inhibitors
This study is an open-label, biomarker-integrated umbrella trial designed to evaluate the clinical efficacy of molecular subtype- and genomic biomarker-guided precision therapies in patients with advanced esophageal cancer refractory to prior immunotherapy. Conducted in a two-step process, the study first enrolls patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on prior immunotherapy, performing circulating tumor DNA (ctDNA) sequencing to stratify them into three distinct treatment cohorts, after which patients receive tailored combination regimens matched to their specific molecular profiling in the second step. Specifically, Cohort 1 includes patients with high EGFR expression or activation of EGFR-related signaling pathways, who will receive Afatinib (40 mg, p.o., Q.D.) combined with Toripalimab (240 mg, i.v., Q21D) in a 21-day treatment cycle, continuing until radiographic disease progression (PD), unacceptable toxicity, loss to follow-up, death, or other investigator-determined criteria for discontinuation, with a maximum toripalimab treatment duration of 24 months. Cohort 2 comprises patients harboring genomic alterations directly associated with cell cycle regulation or activation of cell cycle signaling pathways, who will be treated with Dalpiciclib (125 mg, p.o., Q.D. for 21 consecutive days followed by a 7-day off period in a 28-day cycle [Q4W]) combined with Pyrotinib maleate (320 mg, p.o., Q.D., administered within 30 minutes post-meal, Q4W) until disease progression, unacceptable toxicity, initiation of a new anti-tumor therapy, withdrawal of consent, or investigator's decision for treatment discontinuation. Cohort 3 includes patients with other molecular profiles who do not fit Cohorts 1 or 2, who will receive Camrelizumab (200 mg, i.v., Q3W) and Apatinib (250 mg, p.o., Q.D.), with clinical efficacy evaluations performed every 6 weeks, continuing until radiographic PD, unacceptable toxicity, death, or treatment discontinuation, whichever occurs first. The study aims to recruit an estimated maximum of 90 subjects, enrolling up to 30 subjects per cohort, with the final sample size dependent on the observed toxicities and the prevalence of each molecular cohort within the screened population.
开始日期2026-07-01 |
申办/合作机构- |
ChiCTR2600127200
NeoTRECAMCT-01：A prospective, non-randomized controlled clinical study of SHR-A1811 plus camrelizumab in perioperative combination or sequential chemotherapy for ER(-)/ER(1-10%), HER2-low expressing early or locally advanced breast cancer
开始日期2026-06-30 |
申办/合作机构 |
100 项与 卡瑞利珠单抗 相关的临床结果
登录后查看更多信息
100 项与 卡瑞利珠单抗 相关的转化医学
登录后查看更多信息
100 项与 卡瑞利珠单抗 相关的专利（医药）
登录后查看更多信息
930
项与 卡瑞利珠单抗 相关的文献（医药）2026-12-31·INTERNATIONAL JOURNAL OF HYPERTHERMIA
Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study
Article
作者: Chen, Jinyun ; Wang, Ting ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi
BACKGROUND:
This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.
MATERIALS AND METHODS:
Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.
RESULTS:
All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).
CONCLUSION:
FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.
2026-12-31·ANNALS OF MEDICINE
Cost-effectiveness of adjuvant therapy with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma: from the perspective of the Chinese healthcare system
Article
作者: Shen, Liangfang ; Feng, Yuxin ; Wang, Rui ; Zhou, Qin ; Long, Rong
OBJECTIVE:
Immune checkpoint inhibitors, particularly programmed cell death 1 inhibitors, have shown promising clinical outcomes in the adjuvant treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC), offering a more effective and less toxic treatment option. This study aimed to explore the cost-effectiveness of adjuvant immunotherapy with camrelizumab for patients with LA-NPC from the perspective of the Chinese healthcare system.
METHODS:
A Markov model was developed to evaluate the health and economic outcomes of adjuvant camrelizumab versus standard therapy (observation) in high-risk LA-NPC. Clinical efficacy and safety data were derived from the phase 3 DIPPER trial. The model incorporated three distinct health states and simulated the outcomes over a lifetime horizon. Key endpoints included overall cost, quality-adjusted life year (QALY), incremental cost-effectiveness ratio (ICER), and incremental net health benefit (INHB), assessed at a predefined willingness-to-pay (WTP) threshold of $39,613 per QALY. One-way and probabilistic sensitivity analyses were conducted to assess the robustness of the model.
RESULTS:
Compared with standard therapy, adjuvant camrelizumab for high-risk patients with LA-NPC resulted in an added 4.39 QALYs at an incremental cost of $21,539, yielding an ICER of $4,910/QALY and an INHB of 3.85 QALYs. At the predefined WTP, camrelizumab demonstrated a 98.6% probability of being a cost-effective adjuvant treatment for LA-NPC in China. The health utility value of event-free survival was the most significant parameter influencing the model results. Sensitivity analysis results supported the robustness of the model.
CONCLUSIONS:
In China, adjuvant immunotherapy with camrelizumab following induction-concurrent chemoradiotherapy offers a potentially cost-effective approach for the management of patients with high-risk LA-NPC, yielding an ICER significantly below the predefined WTP threshold.
2026-09-01·Translational Oncology
PD-1/PD-L1 immune checkpoint inhibitors in Hodgkin lymphoma: A meta- and network meta-analysis
Review
作者: Yang, Xiaoyan ; Liu, Zhongyu ; Zhu, Tingxi ; Sun, Huan ; Lu, Zhe ; Lin, Tianchi
BACKGROUND:
Hodgkin lymphoma (HL) is a relatively rare lymphoid malignancy that significantly affects the health of adolescents, young adults and the elderly. Even though conventional chemotherapy offers high cure rates, the relapsed/refractory HL remains challenging.
METHODS:
Pooled single-arm and network meta-analyses were used. Literature search was conducted in PubMed, Embase, Web of Science, the Cochrane Library and Clinical Trials, et al., from the date of establishment dates to August 31, 2025. Studies were screened based on inclusion and exclusion criteria. The primary outcome analyzed was complete response rate (CRR), partial response rate (PRR), and objective response rate (ORR).
RESULTS:
11 single-arm trials and five controlled trials, involving 1602 participants and seven ICI-based treatment strategies were included. The meta-analysis revealed an overall CRR of 0.35, a PRR of 0.37, and an ORR of 0.75 across all therapy methods. Of these, one ICI drug in combination with conventional therapy demonstrated the highest CRR and ORR, while camrelizumab achieved the highest PRR. The treatment strategies with the highest CRR in network meta-analysis was the combination of two ICI drugs. The strategies with the highest PRR were camrelizumab, a single ICI drug, while the strategies with the highest ORR was a single ICI drug combined with conventional therapy.
CONCLUSION:
This study suggests that camrelizumab is associated with an improved PRR for HL, whereas, combination strategy of two ICI drugs, and that one of pembrolizumab and camrelizumab combined with conventional chemoradiotherapy are more effective for elevating the CRR and ORR respectively.
2,756
项与 卡瑞利珠单抗 相关的新闻（医药）2026-07-21
点击蓝字
关注我们
2026年欧洲肿瘤内科学会（ESMO）年会将于10月23~27日在西班牙马德里举办。作为全球肿瘤领域学术影响力突出、覆盖领域全面的年度学术盛会，ESMO每年都会汇聚全球各地的临床肿瘤学专家、科研人员、医药行业从业者与患者倡导者，打造前沿成果互通的多学科交流平台，持续推动肿瘤基础研究向临床实践落地，引领全球肿瘤诊疗的发展趋势。
目前，ESMO官网已公布了本届大会的常规摘要标题及讲者信息（LBA暂未公布）。在此，《肿瘤瞭望消化时讯》特整理了本届ESMO年会中消化系统肿瘤领域入选优选论文专场（Proffered paper session）与快速口头报告专场（Rapid oral session）的重磅临床研究，和您一起先睹为快！（如有疏漏，欢迎评论区留言补充）
Proffered paper session
摘要号：2875O
英文标题：Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: the Phase 3 randomized KEYNOTE-975 study中文标题：帕博利珠单抗或安慰剂联合同步根治性放化疗治疗食管癌及胃食管结合部癌：Ⅲ期随机对照KEYNOTE-975研究讲者：Manish A. Shah | New York, United States of America
摘要号：3530O
英文标题：Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial中文标题：新辅助短程放疗后序贯卡瑞利珠单抗联合化疗治疗局部晚期直肠癌：Ⅲ期UNION研究讲者：张涛 | 华中科技大学同济医学院附属协和医院
摘要号：459O
英文标题：A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer中文标题：一项在既往经治晚期胆道癌患者中比较紫杉醇±Tovecimig的随机研究讲者：Nilofer S. Azad | Baltimore, United States of America
Rapid oral session
摘要号：1007RO
英文标题：Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Monotherapy or in Combination with Cetuximab (Cetux) in Patients (pts) with Advanced/Metastatic Colorectal Cancer (CRC)中文标题：口服KRAS G12D抑制剂INCB161734作为单药或联合西妥昔单抗治疗晚期/转移性结直肠癌患者的安全性与疗效讲者：Jayesh Desai | Melbourne, Australia
摘要号：1008RO
英文标题：IBI363 (TAK-928) plus XELOX as the first line (1L) treatment for advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA)中文标题：IBI363（TAK-928）联合XELOX作为晚期胃或胃食管结合部腺癌（G/GEJA）的一线治疗讲者：俞鹏飞 | 浙江省肿瘤医院
摘要号：1678RO
英文标题：Phase 3 LEAP-012 Study of Lenvatinib + Pembrolizumab vs Dual Placebo With Transarterial Chemoembolization (TACE) for Unresectable Non-metastatic Hepatocellular Carcinoma: Long-term OS Results中文标题：仑伐替尼联合帕博利珠单抗对比双安慰剂联合经动脉化疗栓塞（TACE）用于不可切除非转移性肝细胞癌的Ⅲ期LEAP-012研究长期总生存（OS）结果讲者：Josep M. Llovet | Barcelona, Spain
摘要号：1679RO
英文标题： Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) Monotherapy: First Disclosure of Dose Optimization (DO) and Dose Escalation (DE) Update in Advanced Hepatocellular Carcinoma (HCC)中文标题：BGB-B2033（GPC3×4-1BB双特异性抗体）单药治疗的Ⅰ期研究：首次披露晚期肝细胞癌（HCC）中剂量优化（DO）与剂量递增（DE）的最新结果讲者：Hong Jae Chon | Seongnam, Republic of Korea
摘要号：1680RO
英文标题：Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC): Updated Results中文标题：靶向GPC3并携带TGFβRIIDN的武装自体CAR-T（C-CAR031）在晚期肝细胞癌中的Ⅰ期研究更新结果讲者：梁廷波 | 浙江大学医学院附属第一医院
摘要号：1953RO
英文标题：Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in metastatic colorectal cancer (mCRC): Results from a phase 1/2 study中文标题：CS2009，一种首创的PD-1/VEGF/CTLA-4三特异性抗体，在转移性结直肠癌中的安全性和疗效：一项Ⅰ/Ⅱ期研究的结果讲者：徐瑞华 | 中山大学肿瘤防治中心
摘要号：1954RO
英文标题：INCA33890, a TGFβR2xPD-1 Bispecific Antibody, With Standard of Care (SoC) Anticancer Therapies for Microsatellite Stable Colorectal Cancer (MSS CRC)中文标题：INCA33890，一种TGFβR2/PD-1双特异性抗体，联合标准治疗抗癌疗法用于微卫星稳定型结直肠癌（MSS CRC）讲者：Sreenivasa R. Chandana | Grand Rapids, United States of America
摘要号：2876RO
英文标题：TQB2102, a Novel HER2 Bispecific Antibody-Drug Conjugate, Combined with Bemotrizumab with or without Capecitabine as First-Line Therapy for HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer: A Phase II Study中文标题：TQB2102，一种新型HER2双特异性抗体药物偶联物联合Bemotrizumab±卡培他滨用于HER2阳性晚期胃癌/胃食管结合部癌的一线治疗：一项Ⅱ期研究讲者：徐瑞华 | 中山大学肿瘤防治中心
摘要号：2877RO
英文标题：Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study中文标题：观察等待策略用于Dostarlimab治疗局部性dMMR/MSI-H胃食管腺癌：GERCOR-GONO DEWI Ⅱ期研究首次中期分析结果讲者：Thierry André | Paris, France, CEDEX 12
摘要号：2878RO
英文标题：FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study中文标题：FOLFIRI方案联合雷莫西尤单抗对比紫杉醇联合雷莫西尤单抗用于经紫杉类预处理的晚期或转移性胃食管腺癌患者二线治疗——Ⅲ期IKFs602/AIO RAMIRIS研究最终结果讲者：Sylvie Lorenzen | Munich, Germany
摘要号：2879RO
英文标题：Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma : ARION PRODIGE 67 randomized phase 2 trial中文标题：度伐利尤单抗联合根治性放化疗对比根治性放化疗治疗局部晚期食管癌患者：随机Ⅱ期ARION PRODIGE 67研究讲者：Marie-Anouchka Modesto | Toulouse, France
摘要号：3136RO
英文标题：Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial中文标题：mFOLFIRINOX±SBRT治疗高危、临界可切除或局部晚期胰腺癌患者的随机Ⅱ期研究：AGITG MASTERPLAN研究结果讲者：Andrew Oar | Southport, Australia
摘要号：3137RO
英文标题：Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)中文标题：一种新型口服KRAS G12D抑制剂INCB161734联合化疗用于晚期/转移性胰腺导管腺癌患者的安全性与疗效讲者：Antoine Hollebecque | Villejuif, France
摘要号：787RO
英文标题：Circulating tumor DNA (ctDNA)-guided re-treatment (re-tx) with encorafenib and cetuximab (EC) in patients (pts) with chemorefractory BRAFV600E mutated metastatic colorectal cancer (mCRC): the proof-of-concept single arm phase II BRICKET trial by GONO中文标题：循环肿瘤DNA（ctDNA）指导下的恩考芬尼联合西妥昔单抗（EC）再治疗用于化疗难治性BRAF V600E突变型转移性结直肠癌（mCRC）患者：GONO发起的概念验证性单臂Ⅱ期BRICKET研究讲者：Marco Maria Germani | Pisa, Italy
摘要号：788RO
英文标题：Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: results from the ECLYPse phase II trial中文标题：恩考芬尼联合西妥昔单抗治疗进展后继续联合FOLFIRI方案用于BRAF V600E突变转移性结直肠癌（mCRC）患者：Ⅱ期ECLYPse研究结果讲者：Maria Alessandra Calegari | Rome, Italy
摘要号：789RO
英文标题：TRIDENTE: A phase II study of rechallenge with encorafenib (ENCO), binimetinib (BINI), and cetuximab (CET) in BRAF V600E-mutant metastatic colorectal cancer (mCRC)中文标题：恩考芬尼（ENCO）、比美替尼（BINI）和西妥昔单抗（CET）再挑战用于BRAF V600E突变型转移性结直肠癌（mCRC）的Ⅱ期TRIDENTE研究讲者：Daisuke Kotani | Kashiwa, Japan
摘要号：790RO
英文标题：Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor, in combination with cetuximab ± mFOLFOX6 in patients with KRASG12D-mutated colorectal cancer (CRC)中文标题：QTX3034（一种口服优先靶向G12D的KRAS抑制剂）联合西妥昔单抗±mFOLFOX6用于KRAS G12D突变结直肠癌（CRC）患者的初步临床结果讲者：Ignacio Garrido-Laguna | Salt Lake City, United States of America
摘要号：791RO
英文标题：Long-term follow-up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study中文标题：Telisotuzumab Adizutecan（ABBV-400，Temab-A）联合贝伐珠单抗对比标准治疗用于三线及以上结直肠癌患者的长期随访：一项Ⅰ期研究的更新结果讲者：Michael Cecchini | New Haven, United States of America
（来源：肿瘤瞭望消化时讯）
声 明
凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
2026-07-21
·肿瘤界
点击蓝字 关注我们
//
2026年10月23日至27日，全球肿瘤领域顶级学术盛会——欧洲肿瘤内科学会（ESMO）年会将在西班牙马德里隆重召开。作为国际肿瘤学领域最具权威性与影响力的学术盛会之一，本届大会将全面汇聚全球肿瘤基础研究、转化医学及临床前沿研究成果，为全球临床诊疗革新、多学科学术交流搭建平台，助力全球肿瘤诊疗水平持续进阶。
日前，ESMO官网公布了本届大会非LBA类摘要标题。其中，共有47项中国学者主导的研究成功入选口头汇报环节（包括Proffered Paper session和Rapid Oral session），充分印证了中国肿瘤科研实力的飞速成长。为此，本文特整理本届大会中国专家重磅入选研究，聚焦本土原创科研成果，荟萃前沿学术进展，以飨广大临床从业者与科研工作者。
消化系统肿瘤
摘要号：1680RO
研究名称（英文）：Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC): Updated Results
研究名称（中文）：C-CAR031（一种靶向GPC3且经TGFβRII显性负性修饰的自体CAR-T细胞）治疗晚期肝细胞癌的I期研究结果
讲者：梁廷波 | 浙江大学医学院附属第一医院
报告类型：Rapid Oral session
摘要号：2876RO
研究名称（英文）：TQB2102, a Novel HER2 Bispecific Antibody-Drug Conjugate, Combined with Bemotrizumab with or without Capecitabine as First-Line Therapy for HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer: A Phase II Study
研究名称（中文）：新型HER2双特异性抗体药物偶联物TQB2102联合Bemotrizumab±卡培他滨一线治疗HER2阳性晚期胃癌/胃食管结合部癌：一项Ⅱ期研究
讲者：徐瑞华 | 中山大学肿瘤防治中心
报告类型：Rapid Oral session
摘要号：3530O
研究名称（英文）：Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial
研究名称（中文）：新辅助短程放疗序贯卡瑞利珠单抗联合化疗治疗局部晚期直肠癌（LARC）：Ⅲ期UNION试验
讲者：张涛 | 华中科技大学同济医学院附属协和医院
报告类型：Proffered Paper session
乳腺癌
摘要号：4RO
研究名称（英文）：Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial
研究名称（中文）：转移性乳腺癌 ADC 经治后采用同载荷新型 ADC 的靶点转换研究：一项前瞻性、开放标签的 II 期平台试验（SWITCH）
讲者：刘西禹 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral Session
摘要号：5RO
研究名称（英文）：Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer
研究名称（中文）：新型 B7-H3 靶向抗体药物偶联物 SYS6043 在晚期乳腺癌患者中的安全性与疗效
讲者：王红霞 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral session
摘要号：4639RO
研究名称（英文）：Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01
研究名称（中文）：芦康沙妥珠单抗对比化疗治疗经治局部复发或转移性三阴性乳腺癌的最终总生存分析：III 期 OptiTROP-Breast01 研究
讲者：樊英 | 中国医学科学院肿瘤医院
报告类型：Rapid Oral session
摘要号：4640RO
研究名称（英文）：Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (TopI)-Based ADCs: Results from a Phase 2 Study
研究名称（中文）：Bulumtatug fuvedotin (BFv, 9MW2821)，一种靶向 Nectin-4 的抗体药物偶联物，用于既往接受过拓扑异构酶 I 抑制剂类 ADC 治疗的局部晚期或转移性三阴性乳腺癌患者：一项II期研究结果
讲者：张剑 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral session
胸部肿瘤
摘要号：2615RO
研究名称（英文）：Dalmelitinib plus Aumolertinib versus platinum-based chemotherapy in advanced NSCLC patients with MET amplification post EGFR TKI: a randomized, phase 3 study
研究名称（中文）：EGFR-TKI 治疗后进展、合并 MET 扩增晚期非小细胞肺癌：Dalmelitinib联合阿美替尼对比含铂化疗的随机 III 期临床研究
讲者：陆舜 | 上海市胸科医院
报告类型：Rapid Oral session
摘要号：2616RO
研究名称（英文）：A phase 2 study of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer (NSCLC)
研究名称（中文）：全球首创 PD-1/VEGF/CTLA-4 三特异性抗体 CS2009 治疗晚期非小细胞肺癌的 II 期临床研究
讲者：熊安稳 | 同济大学附属东方医院
报告类型：Rapid Oral session
摘要号：4156RO
研究名称（英文）：Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: interim results from the iTHYM phase II study
研究名称（中文）：依沃西单抗联合化疗一线治疗复发 / 转移性胸腺癌：iTHYM II 期研究中期数据
讲者：侯雪 | 中山大学肿瘤防治中心
报告类型：Rapid Oral session
泌尿系统肿瘤
摘要号：1209RO
研究名称（英文）：Neoadjuvant toripalimab combined with chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial
研究名称（中文）：新辅助特瑞普利单抗联合化疗治疗局部晚期阴茎鳞状细胞癌：一项多中心、前瞻性、单臂、II期临床试验
讲者：韩辉 | 中山大学肿瘤防治中心
报告类型：Rapid Oral session
摘要号：3592RO
研究名称（英文）：Efficacy and Safety of AK112 (Ivonescimab), a PD-1/VEGF Bispecific Antibody, as First-Line Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma (aRCC): Results from a Phase Ib/II Study
研究名称（中文）：AK112（依沃西单抗，一种PD-1/VEGF双特异性抗体）作为IMDC预后良好晚期肾细胞癌（aRCC）患者一线治疗的疗效和安全性：一项Ib/II期研究的结果
讲者：鄢谢桥 | 北京大学肿瘤医院
报告类型：Rapid Oral session
摘要号：4739RO
研究名称（英文）：Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
研究名称（中文）：芦康沙妥珠单抗(Sac-TMT) +帕博利珠单抗 (Pembro) 用于局部晚期或转移性尿路上皮癌 (la/mUC)：一项 2 期研究的结果 (2870-002/SKB264-II-06)
讲者：卞晓洁 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral Session
妇科肿瘤
摘要号：1240RO
研究名称（英文）：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial
研究名称（中文）：艾帕洛利托沃瑞利单抗（QL1706）＋化疗±贝伐珠单抗一线治疗持续性、复发或转移性宫颈癌（R/M CC）：一项双盲、随机、安慰剂对照Ⅲ期试验结果
讲者：刘继红 | 中山大学肿瘤防治中心
报告类型：Rapid Oral session
摘要号：1243RO
研究名称（英文）：JSKN033, a first-in-class subcutaneous (SC)-injected fixed-dose combination (FDC) of biparatopic anti-HER2 ADC and PD-L1 inhibitor, in pre-treated cervical cancer
研究名称（中文）：JSKN033——全球首创皮下注射型双表位抗HER2 ADC与PD-L1抑制剂固定剂量复方制剂，用于经治宫颈癌
讲者：吴小华 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral session
摘要号：1244RO
研究名称（英文）：SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study
研究名称（中文）：新型靶向nectin-4抗体药物偶联物SHR-A2102治疗复发或转移性宫颈癌：II期研究结果
讲者：刘继红 | 中山大学肿瘤防治中心
报告类型：Rapid Oral session
头颈肿瘤
摘要号：1541RO
研究名称（英文）：Perioperative Cetuximab combined with Toripalimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-arm, Phase II Study
研究名称（中文）：围手术期西妥昔单抗联合特瑞普利单抗用于局部复发可切除头颈部鳞状细胞癌：前瞻性、单臂、II期研究
讲者：鞠侯雨 | 上海交通大学医学院附属第九人民医院
报告类型：Rapid Oral session
摘要号：1542RO
研究名称（英文）：Phase II Study of Izalontamab Brengitecan (iza-bren) Plus Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
研究名称（中文）：伦康依隆妥单抗（iza-bren）联合帕博利珠单抗治疗复发或转移性头颈部鳞状细胞癌患者的II期研究
讲者：季冬梅 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral session
血液系统恶性肿瘤
摘要号：1456O
研究名称（英文）：A first-in-human phase I study of LBL-034, a GPRC5D/CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM)
研究名称（中文）：GPRC5D/CD3 双特异性抗体 LBL-034 用于复发 / 难治性多发性骨髓瘤的首次人体I期临床研究
讲者：窦雪琳 | 北京大学人民医院
报告类型：Proffered Paper session
摘要号：1457O
研究名称（英文）：First Report of a Phase Ib Study of Rocbrutinib, a Fourth-Generation Bruton’s Tyrosine Kinase Inhibitor, Combined with R-CHOP in Patients with Previously Untreated B-Cell Lymphoma
研究名称（中文）：四代布鲁顿酪氨酸激酶抑制剂洛布替尼联合 R-CHOP 方案治疗初治 B 细胞淋巴瘤患者的Ib 期临床研究首次报道
讲者：蔡清清 | 中山大学肿瘤防治中心
报告类型：Proffered Paper session
摘要号：1458O
研究名称（英文）：Safety and Efficacy of TRS005, a Novel Anti-CD20 Antibody-Drug Conjugate, in Patients with Transformed Diffuse Large B-Cell Lymphoma: Results from a Phase I Study
研究名称（中文）：新型抗CD20抗体偶联药物TRS005在转化型弥漫大B细胞淋巴瘤患者中的安全性与有效性：I期研究结果
讲者：石远凯 | 中国医学科学院肿瘤医院
报告类型：Proffered Paper session
肉瘤
摘要号：3714O
研究名称（英文）：HH2853, an EZH1/2 Inhibitor, in Patients with Epithelioid Sarcoma: promising anti-tumor activity Results from the pivotal phase II (HH2853-G101 cohort 2) study
研究名称（中文）：EZH1/2抑制剂HH2853在上皮样肉瘤患者中的应用：关键性II期研究（HH2853-G101队列2）的抗肿瘤活性结果
讲者：樊征夫 | 北京大学肿瘤医院
报告类型：Proffered Paper session
摘要号：3720RO
研究名称（英文）：Nab-paclitaxel plus pegylated liposomal doxorubicin in advanced or unresectable malignant vascular tumors: results from a phase II study
研究名称（中文）：白蛋白结合型紫杉醇联合聚乙二醇化脂质体阿霉素在晚期或不可切除恶性血管肿瘤中的应用：II期研究结果
讲者：张星 | 中山大学肿瘤防治中心
报告类型：Rapid Oral session
神经内分泌肿瘤与内分泌肿瘤
摘要号：2392O
研究名称（英文）：Opamtistomig (LBL-024), a novel PD-L1×4-1BB bispecific antibody, combined with chemotherapy as first-line treatment for advanced extrapulmonary neuroendocrine carcinoma: results from a phase Ib/II trial
研究名称（中文）：新型 PD-L1×4-1BB 双特异性抗体 Opamtistomig（LBL-024）联合化疗一线治疗晚期肺外神经内分泌癌的 Ib/II 期临床研究结果
讲者：张盼盼 | 北京大学肿瘤医院
报告类型：Proffered Paper session
摘要号：2393O
研究名称（英文）：First results from a phase 2 trial of second-line pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in unresectable neuroendocrine neoplasms
研究名称（中文）：PD-L1×VEGF-A 双特异性抗体 Pumitamig 联合化疗用于不可切除神经内分泌肿瘤二线治疗的 II 期临床初步结果
讲者：徐建明 | 解放军总医院
报告类型：Proffered Paper session
摘要号：2394RO
研究名称（英文）：Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma
研究名称（中文）：索凡替尼联合 EP 方案 + 斯鲁利单抗一线治疗晚期肺外神经内分泌癌最新疗效与安全性分析
讲者：Haihong Wang | 武汉
报告类型：Rapid Oral Session
摘要号：4211RO
研究名称（英文）：The efficacy and safety of becotatug vedotin and pucotenlimab in EGFR-positive unresectable anaplastic/ poorly differentiated thyroid cancer: preliminary results from a phase II clinical trial
研究名称（中文）：维贝柯妥塔单抗联合普特利单抗治疗 EGFR 阳性不可切除间变性 / 低分化甲状腺癌的 II 期临床初步疗效与安全性数据
讲者：王宇 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral session
中枢神经系统肿瘤
摘要号：701RO
研究名称（英文）：Clinical Activity and Safety of Novel Brain-Penetrant BRAF Inhibitor HSK42360 in BRAF V600-Mutated Gliomas: Initial Results from a Phase 1 Study
研究名称（中文）：新型血脑屏障穿透型 BRAF 抑制剂 HSK42360 用于 BRAF V600 突变胶质瘤的临床疗效与安全性：I期研究初步数据
讲者：李文斌 | 首都医科大学附属北京天坛医院
报告类型：Rapid Oral session
摘要号：702RO
研究名称（英文）：Immune checkpoint blockade for patients with leptomeningeal metastases from non-small cell lung cancer
研究名称（中文）：非小细胞肺癌脑膜转移患者的免疫检查点抑制治疗
讲者：郑媚美 | 广东省人民医院
报告类型：Rapid Oral session
新兴疗法
摘要号：999O
研究名称（英文）：Elfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) + pumitamig (PD-L1 x VEGF-A bsAb) in patients with advanced solid tumors: First results from a global phase 2 trial
研究名称（中文）：Elfetabart drozuntecan（Elfe-D；DB-1311/BNT324，B7H3 抗体偶联药物）联合 pumitamig（PD-L1×VEGF-A 双特异性抗体）治疗晚期实体瘤：一项全球II期临床试验的首次研究数据
讲者：郭晔 | 上海市东方医院
报告类型：Proffered Paper session
摘要号：1000O
研究名称（英文）：HS-20122, a Novel EGFR/cMET Bispecific Antibody Drug Conjugate, in Advanced Solid Tumors
研究名称（中文）：新型EGFR/cMET双特异性抗体偶联药物HS-20122在晚期实体瘤中的应用
讲者：赵洪云 | 中山大学肿瘤防治中心
报告类型：Proffered Paper session
摘要号：1001O
研究名称（英文）：Safety and efficacy of IBI3001, an anti-EGFR/B7H3 bispecific ADC, in patients (pts) with advanced solid tumors: Results of a multi-regional phase 1 study
研究名称（中文）：抗EGFR/B7H3双特异性ADC IBI3001在晚期实体瘤患者中的安全性与有效性：多中心I期研究结果
讲者：胡毅 | 解放军总医院
报告类型：Proffered Paper session
摘要号：1003O
研究名称（英文）：Phase I study of GCC CAR-T therapy in patients with advanced colorectal cancer
研究名称（中文）：GCC CAR-T疗法治疗晚期结直肠癌患者的I期临床研究
讲者：刘畅 | 北京大学肿瘤医院
报告类型：Proffered Paper session
摘要号：1008RO
研究名称（英文）：IBI363 (TAK-928) plus XELOX as the first line (1L) treatment for advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA)
研究名称（中文）：IBI363（TAK-928）联合XELOX一线治疗晚期胃或胃食管交界部腺癌
讲者：俞鹏飞 | 浙江省肿瘤医院
报告类型：Rapid Oral session
摘要号：1009RO
研究名称（英文）：JMT108, a novel anti-PD-1/IL-15 bifunctional fusion protein, in patients with advanced solid tumors: results from a first-in-human phase I/II study
研究名称（中文）：新型抗PD-1/IL-15双功能融合蛋白JMT108治疗晚期实体瘤：首次人体I/II期研究结果
讲者：林榕波 | 福建省肿瘤医院
报告类型：Rapid Oral session
探索性免疫疗法
摘要号：1949O
研究名称（英文）：Phase 1b/2 study of anti-CCR8 antibody QLP2117 plus anti-PD-1 antibody QL2107 in patients (pts) with advanced solid tumors
研究名称（中文）：抗 CCR8 抗体 QLP2117 联合抗 PD-1抗体 QL2107 用于晚期实体瘤患者的Ib/II 期临床研究
讲者：王峰 | 中山大学肿瘤防治中心
报告类型：Proffered Paper session
摘要号：1950RO
研究名称（英文）：Phase 1b/2a study of LK101, a personalized neoantigen DC vaccine, as first-line maintenance therapy in locally advanced/metastatic NSCLC
研究名称（中文）：LK101（一种个性化新抗原树突状细胞疫苗）用于局部晚期/转移性非小细胞肺癌一线维持治疗的1b/2a期研究
讲者：王洁 | 中国医学科学院肿瘤医院
报告类型：Rapid Oral session
摘要号：1952RO
研究名称（英文）：IBI363 (TAK-928) plus bevacizumab (Bev) vs docetaxel (DTX) in patients (pts) with locally advanced or metastatic immunotherapy (IO)-resistant lung adenocarcinoma (LUAC) without actionable genomic alterations: a randomized phase Ib study
研究名称（中文）：IBI363 (TAK-928) 联合贝伐珠单抗对比多西他赛治疗无驱动基因变异的局部晚期或转移性免疫治疗耐药肺腺癌患者的随机1b期研究
讲者：周建娅 | 浙江大学医学院附属第一医院
报告类型：Rapid Oral session
摘要号：1953RO
研究名称（英文）：Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in metastatic colorectal cancer (mCRC): Results from a phase 1/2 study
研究名称（中文）：CS2009（一种首创的 PD-1/VEGF/CTLA-4 三特异性抗体）在转移性结直肠癌中的安全性与疗效：一项 1/2 期研究结果
讲者：徐瑞华 | 中山大学肿瘤防治中心
报告类型：Rapid Oral session
基础科学与转化研究
摘要号：384RO
研究名称（英文）：L. reuteri derived conjugated linoleic acid boosts anti-PD1 therapy by disengaging the Cbl-b immune brake in NSCLC
研究名称（中文）：罗伊氏乳杆菌来源共轭亚油酸通过解除 Cbl-b 免疫检查点增强 PD-1 抑制剂在非小细胞肺癌中的抗肿瘤疗效
讲者：宋倩 | 山东省肿瘤医院
报告类型：Rapid Oral session
摘要号：386RO
研究名称（英文）：Stroma-targeted antibody-drug conjugate therapy against GPNMB⁺ macrophages dismantles the pre-metastatic niche and intercepts lymphatic dissemination in prostate cancer
研究名称（中文）：靶向基质的抗体药物偶联物治疗通过清除 GPNMB⁺ 巨噬细胞，瓦解前列腺癌转移前微环境并阻断淋巴扩散
讲者：倪旭栋 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral session
摘要号：4241O
研究名称（英文）：Multi-omics profiling defines drivers, organotropism, and predictive models in RCC metastasis
研究名称（中文）：多组学图谱揭示肾细胞癌转移的驱动基因、器官嗜性及预测模型
讲者：Maoping Cai | 上海
报告类型：Proffered Paper session
摘要号：4243O
研究名称（英文）：Single-cell transcriptomic analysis of EGFR-mutant lung adenocarcinoma reveals dynamic tumor ecosystem subtypes during TKI treatment
研究名称（中文）：单细胞转录组解析 EGFR 突变肺腺癌 TKI 治疗过程中动态肿瘤微环境亚型变化
讲者：万诗乐 | 上海市肺科医院
报告类型：Proffered Paper session
人工智能与数字健康
摘要号：170O
研究名称（英文）：RADIANT: a radiotherapy foundation model for treatment planning and outcome prediction across cancers
研究名称（中文）：RADIANT：一种用于跨癌种治疗计划与疗效预测的放射治疗基础模型
讲者：张臻 | 浙江省肿瘤医院
报告类型：Proffered Paper session
摘要号：172RO
研究名称（英文）：An Agentic AI System Augmenting Multidisciplinary Decision-Making in Perihilar Cholangiocarcinoma: From Development to Prospective Clinical Validation
研究名称（中文）：一种增强肝门部胆管癌多学科决策的主动式人工智能系统：从开发到前瞻性临床验证
讲者：黄燕琪 | 广东省人民医院
报告类型：Rapid Oral session
摘要号：173RO
研究名称（英文）：Artificial intelligence–assisted preoperative communication for patients with prostate cancer: a prospective, single-blinded, randomized phase II trial
研究名称（中文）：人工智能辅助前列腺癌患者术前沟通：一项前瞻性、单盲、随机Ⅱ期试验
讲者：刘铮 | 复旦大学附属肿瘤医院
报告类型：Rapid Oral session
支持治疗与姑息治疗
摘要号：3894O
研究名称（英文）：rhTPO Prevention for Cancer-Treatment-Induced-Thrombocytopenia and Cardiac-Injury in Cancer Patients: A Multicenter Randomized Controlled Trial (CCORG-001)
研究名称（中文）：rhTPO 预防癌症患者癌症治疗引起的血小板减少症和心脏损伤：一项多中心随机对照试验 (CCORG-001)
讲者：田莉莉 | 大连医科大学附属第一医院
报告类型：Proffered Paper session
备注：排名不分先后，按照摘要号进行排序
如有遗漏或任何问题，请给我们留言~
声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。
来源：医脉通肿瘤科、ESMO官网
编辑：Lagertha
审核：阿希雅
2026-07-20
编者按：2026年欧洲肿瘤内科学会（ESMO）年会将于10月23日至27日在西班牙马德里举办，汇聚全球临床肿瘤学专家、科研人员、医药行业从业者与患者领袖，广泛交流前沿成果，引领全球肿瘤诊疗发展。目前，ESMO官网已公布大会口头报告及壁报标题，最新突破摘要（LBA）尚未披露，中国研究者再次为全球贡献了大量创新研究和临床经验。基于现有信息，《肿瘤瞭望》特别整理中国学者在ESMO头颈部瘤领域（不含甲状腺癌）带来的最新进展，供大家提前参考了解。内容若有疏漏谬误，敬请留言指正。
快速口头报告专场：头颈部肿瘤
时间：2026年10月25日（周日）14:45 - 16:15
地点：Murcia Auditorium - Hall 3
摘要号：1541RO
标题： Perioperative Cetuximab combined with Toripalimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-arm, Phase II Study
中文标题：西妥昔单抗联合特瑞普利单抗用于局部复发可切除的头颈部鳞状细胞癌围术期治疗：一项前瞻性、单臂、II期研究
讲者：鞠侯雨 教授
单位：上海交通大学医学院附属第九人民医院
摘要号：1542RO
标题： Phase II Study of Izalontamab Brengitecan (iza-bren) Plus Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
中文标题：伦康依隆妥单抗（Iza-bre）n联合帕博利珠单抗治疗复发或转移性头颈部鳞状细胞癌（R/M HNSCC）患者的II期研究
讲者：季冬梅 教授
单位：复旦大学附属肿瘤医院
多学科专场：鼻咽癌诊疗模式改变
时间：2026年10月25日（周日）10:15 - 11:30
地点：Pamplona Auditorium - Hall 5
标题：The role of medical oncologist
中文标题：肿瘤内科医生在鼻咽癌多学科诊疗的角色
讲者：马碧如 教授（Brigette B. Ma）
单位：香港中文大学医院
壁报（Posters）
摘要号：1545P
标题： A Phase II Clinical Study of Toripalimab Maintenance Therapy for High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) following a Complete Response (CR) to Standard of Care (SOC)
中文标题：经标准治疗达到完全缓解的高危局部晚期头颈部鳞状细胞癌（LA-HNSCC）应用特瑞普利单抗维持治疗的II期临床研究
讲者：陈蓓 教授
单位：南方医科大学南方医院
摘要号：1546P
标题： Radiotherapy Alone versus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Patients Obtaining CR/PR after Neoadjuvant Chemotherapy: A Randomized, Multicenter, Phase 3 Trial – Updated Analysis with Mature Follow-up
中文标题：单纯放疗对比同步放化疗用于新辅助化疗后完全缓解/部分缓解的鼻咽癌患者：一项随机、多中心、III期试验——随访数据成熟后的更新分析
讲者：金厅 教授
单位：浙江省肿瘤医院
摘要号：1551P
标题： Autologous Latent Membrane Protein 2 Specific T-cell Receptor-Engineered T Cell Therapy for Epstein–Barr Virus-Related Nasopharyngeal Carcinoma: a First-in-class Phase I Trial
中文标题：自体潜伏膜蛋白2特异性T细胞受体工程化T细胞疗法治疗EB病毒相关鼻咽癌：一项首创I期试验
讲者：Yifu Li (Guangzhou, China)
摘要号：1552P
标题： Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil in N2-3 nasopharyngeal carcinoma: final analysis of a multicenter, open-label, phase 3 randomised trial
中文标题：同步放化疗后顺铂-吉西他滨对比顺铂-氟尿嘧啶辅助治疗N2-3期鼻咽癌：一项多中心、开放标签、III期随机试验的最终分析
讲者：程慧琳 教授
单位：中山大学孙逸仙纪念医院
摘要号：1554P
标题： Efficacy and Safety of Tislelizumab Plus Induction Chemotherapy Followed by Concurrent IMRT and CIRT for T4/N3 Nasopharyngeal Carcinoma: Preliminary Results of a Multicenter Phase II Trial
中文标题：替雷利珠单抗联合诱导化疗后IMRT与CIRT同步治疗T4/N3期鼻咽癌的疗效和安全性：一项多中心II期试验的初步结果
讲者：胡超苏 教授
单位：复旦大学附属肿瘤医院
摘要号：1556P
标题： Long-Term Outcomes of Reduced-Dose Radiotherapy in Patients with Epstein-Barr Virus DNA-Selected Stage III Nasopharyngeal Carcinoma: A 5-Year Follow-Up Secondary Analysis of a Phase II Trial
中文标题：减量放疗在经EB病毒DNA筛选的III期鼻咽癌患者中的长期结局：一项II期试验的5年随访二次分析
讲者：Yu-Xi Xiao
单位：中山大学肿瘤防治中心
摘要号：1557P
标题： Neoadjuvant Pembrolizumab Combined with Low-Dose Cisplatin and 5-Fluorouracil for Locally Advanced Head and Neck Squamous Cell Carcinoma: Updated Data from a Single-Arm, Multicenter Clinical Trial.
中文标题：帕博利珠单抗联合低剂量顺铂和5-FU新辅助治疗局部晚期头颈部鳞状细胞癌：一项单臂、多中心临床试验的更新数据
讲者：葛明华 教授
单位：浙江省人民医院
摘要号：1558P
标题： Neoadjuvant SBRT Sequential Tislelizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase II Trial (NEOSTART)
中文标题：新辅助SBRT序贯替雷利珠单抗治疗局部晚期头颈部鳞状细胞癌：一项单臂II期试验（NEOSTART）
讲者：Yani Zhang
单位：中山大学肿瘤防治中心
摘要号：1561P
标题： Neoadjuvant finotonlimab plus platinum-taxane chemotherapy for locally advanced HPV-negative head and neck squamous cell carcinoma: a prospective phase II study
中文标题：菲诺利单抗联合铂类、紫杉类新辅助治疗局部晚期HPV阴性头颈部鳞状细胞癌：一项前瞻性II期研究
讲者：江明杰 教授
单位：中山大学肿瘤防治中心
摘要号：1562P
标题： Pembrolizumab Plus Chemotherapy as First‑Line Treatment for Recurrent/Metastatic Sinonasal Squamous Cell Carcinoma: Three‑Year Follow‑Up of the First Prospective Phase II Study
中文标题：帕博利珠单抗联合化疗一线治疗复发/转移性鼻窦鳞状细胞癌：首项前瞻性II期研究的3年随访结果
讲者：桂琳 教授
单位：中国医学科学院肿瘤医院
摘要号：1565P
标题：Sintilimab combined with bevacizumab and induction chemotherapy in the treatment of N2-3 nasopharyngeal carcinoma: A Prospective, single-arm, multicenter phase II clinical study
中文标题：信迪利单抗联合贝伐珠单抗及诱导化疗治疗N2-3期鼻咽癌：一项前瞻性、单臂、多中心II期临床研究
讲者：陶嫦娟 教授
单位：浙江省肿瘤医院
摘要号：1566P
标题：Stereotactic Body Radiotherapy Combined with Chemotherapy and PD-1 Inhibitor in Oligometastatic Nasopharyngeal Carcinoma (STOMP): A Prospective Phase II Clinical Trial
中文标题：立体定向体部放疗联合化疗及PD-1单抗治疗寡转移鼻咽癌（STOMP）：一项前瞻性II期临床试验
讲者：苗菁菁 教授
单位：中山大学肿瘤防治中心
摘要号：1574P
标题：Evaluation of autologous tumor-infiltrating lymphocytes (GT201) plus toripalimab in recurrent or metastatic head and neck cancer
中文标题：自体肿瘤浸润淋巴细胞（GT201）联合特瑞普利单抗治疗复发或转移性头颈癌的效果评估
讲者：何悦 教授
单位：上海交通大学医学院附属第九人民医院
摘要号：1576P
标题：Neoadjuvant Iparomlimab and Tuvonralimab (PD-1/CTLA-4 bifunctional antibody) Combined With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
中文标题：艾帕洛利托沃瑞利单抗（PD-1/CTLA-4双功能抗体）联合化疗新辅助治疗局部晚期头颈部鳞状细胞癌
讲者：魏玉梅 教授
单位：山东省第二人民医院
摘要号：1577P
标题：Neoadjuvant Tislelizumab Plus Chemotherapy Followed by Adjuvant Tislelizumab for Locally Advanced Nasopharyngeal Carcinoma: updated analysis
中文标题：替雷利珠单抗联合化疗新辅助治疗后替雷利珠单抗辅助治疗局部晚期鼻咽癌：更新分析
讲者：孙士然 教授
单位：中国医学科学院肿瘤医院
摘要号：1586P
标题：Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in nonmetastatic nasopharyngeal carcinoma treated with intensity modulated radiotherapy (IMRT) + carbon-ion beam radiotherapy (CIRT)
中文标题：诱导化疗后循环EBV DNA水平对非转移性鼻咽癌IMRT联合CIRT治疗预后判断
讲者：李玉姣 教授
单位：复旦大学附属肿瘤医院
摘要号：1589P
标题：Strategy of Combing Immunology with Locoregional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma: Sequential or Concurrent?
中文标题：初诊转移性鼻咽癌中免疫联合局部放疗的策略：序贯还是同步？
讲者：Lin-Fang Wu (Guangzhou, China)
摘要号：1590P
标题：Comparison of Efficacy Between 2 and 3 Cycles of Neoadjuvant Immunotherapy Combined with Chemotherapy for Head and Neck Squamous Cell Carcinoma
中文标题：头颈部鳞状细胞癌新辅助免疫治疗联合化疗2周期与3周期疗效比较
讲者：陈晓红 教授
单位：首都医科大学附属北京同仁医院
摘要号：1592P
标题：Efficacy of Immediate Radiotherapy Versus Salvage Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma Patients Responsive to Chemoimmunotherapy
中文标题：化疗联合免疫治疗有应答的初治转移性鼻咽癌患者行即刻放疗对比挽救放疗的疗效分析
讲者：Qitong Zhang (Guangzhou, China)
电子壁报（ePosters）
摘要号：1596eP
标题： Development of a Multimodal Deep Learning Prognostic Model Based on Recursive Attention Mechanisms for Nasopharyngeal Carcinoma
中文标题：基于递归注意力机制的多模态深度学习预后模型在鼻咽癌中的构建
讲者：Ying Zeng (Zhanjiang, China)
摘要号：1597eP
标题： Cross-Sectional Delta-Radiomics: A novel approach for NPC Staging and Prognosis
中文标题：横断面德尔塔影像组学：一种鼻咽癌分期与预后评估的新方法
讲者：袁晞朗 教授（Adams Hei Long Yuen）
单位：香港东华学院
摘要号：1601eP
标题： Proteomic profling identifies the CD23-positive FDC network as a prognostic biomarker for metastasis in nasopharyngeal carcinoma
中文标题：蛋白组学分析鉴定CD23阳性FDC网络作为鼻咽癌转移预后生物标志物
讲者：Yu Chen (Guangzhou, China)
摘要号：1606eP
标题：Updated long-term survival outcomes of neoadjuvant anti-PD1 with low-dose cisplatin/5-fluorouracil in locally advanced head and neck squamous cell carcinoma: a phase II single-arm study
中文标题：PD-1单抗联合低剂量顺铂/5-氟尿嘧啶治疗局部晚期头颈部鳞状细胞癌的长期生存结果更新：一项单臂II期研究
讲者：徐加杰 教授
单位：浙江省人民医院
摘要号：1626eP
标题：First-Line Gemcitabine and Cisplatin Plus Camrelizumab and Apatinib in Nasopharyngeal Carcinoma with Liver Metastasis: Interim Analysis
中文标题：吉西他滨+顺铂联合卡瑞利珠单抗及阿帕替尼一线治疗伴肝转移鼻咽癌：中期分析
讲者：夏伟雄 教授
单位：中山大学肿瘤防治中心
摘要号：1628eP
标题：Immunotherapy rechallenge with cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) versus PD-1 inhibitors in anti-PD-1 resistant recurrent/metastatic nasopharyngeal carcinoma
中文标题：卡度尼利单抗（PD-1/CTLA-4双特异性抗体）对比PD-1单抗用于PD-1单抗耐药复发/转移性鼻咽癌的免疫再挑战研究
讲者：Yaofei Jiang (Nanchang, China)
摘要号：1643eP
标题：VAV1 Drives a Functional Switch Linking Tumor Progression to Immune Evasion in Head and Neck Squamous Cell Carcinoma
中文标题：VAV1 驱动头颈部鳞状细胞癌中连接肿瘤进展与免疫逃逸的功能性转变作用
讲者：Taonong Cai (Guangzhou, China)
摘要号：1647eP
标题：Preoperative Neoadjuvant Therapy for Oropharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis Comparing Immunochemotherapy and Chemotherapy
中文标题：口咽部鳞状细胞癌术前新辅助治疗：免疫联合化疗对比化疗的单中心回顾性分析
讲者：陈晓红 教授
单位：首都医科大学附属北京同仁医院
摘要号：1648eP
标题：Preoperative Neoadjuvant Therapy for Poorly Differentiated Head and Neck Squamous Cell Carcinoma: A Single-Center Retrospective Analysis Comparing Immunochemotherapy and Chemotherapy
中文标题：低分化头颈部鳞状细胞癌术前新辅助治疗：免疫联合化疗对比化疗的单中心回顾性分析
讲者：陈晓红 教授
单位：首都医科大学附属北京同仁医院
摘要号：1659eP
标题：Association of n-6/n-3 Ratio Elevation Induced by Radiotherapy-Driven Omega-3 Depletion with Severe Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma
中文标题：鼻咽癌中放疗驱动Omega-3耗竭致n-6/n-3比值升高与严重放射性口腔黏膜炎的关联性分析
讲者：罗海清 教授
单位：广东医科大学附属医院
摘要号：1662eP
标题：Watch-and-Wait Versus Immediate Radiotherapy in de novo Metastatic Nasopharyngeal Carcinoma: Survival and Toxicity Outcomes After First-Line Chemotherapy
中文标题：初治转移性鼻咽癌一线化疗后观察等待对比即刻放疗：生存与毒性结局
讲者：Shuhui Dong (Guangzhou, China)
摘要号：1663eP
标题：Bacteroides sp. DH3716P Enhances Immunotherapy Response in Oligometastatic Nasopharyngeal Carcinoma via the Gut–Nasopharyngeal Axis
中文标题：拟杆菌属 DH3716P 通过"肠–鼻咽轴"增强寡转移鼻咽癌的免疫治疗应答
讲者：Zhenhua Zhou (Guangzhou, China)
摘要号：1672eTiP
标题：A Single-Arm, Prospective Phase II Clinical Study on the Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)
中文标题：替雷利珠单抗+西妥昔单抗+化疗新辅助序贯挽救手术及辅助替雷利珠单抗+西妥昔单抗治疗可切除局部复发口腔及口咽鳞癌（OSCC）的单臂前瞻性II期研究
讲者：林承重 教授
单位：复旦大学附属中山医院
摘要号：1676eTiP
标题：Ivonescimab Combined with Chemotherapy as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Prospective, Open-Label, Single-Arm Phase II Study
中文标题：依沃西单抗联合化疗一线治疗复发或转移性头颈鳞癌：一项前瞻性、开放标签、单臂II期研究
讲者：刘平 教授
单位：中南大学湘雅二医院
（来源：《肿瘤瞭望》编辑部）
声 明
凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
100 项与 卡瑞利珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 转移性宫颈癌 | 中国 | 2025-05-13 | |
| 复发性宫颈癌 | 中国 | 2025-05-13 | |
| 晚期肝细胞癌 | 中国 | 2023-01-31 | |
| 晚期鼻咽癌 | 中国 | 2021-04-27 | |
| 食管鳞状细胞癌 | 中国 | 2020-06-17 | |
| 非小细胞肺癌 | 中国 | 2020-06-17 | |
| 肝细胞癌 | 中国 | 2020-03-05 | |
| 霍奇金淋巴瘤 | 中国 | 2019-05-29 | |
| 霍奇金淋巴瘤 | 中国 | 2019-05-29 | |
| 非鳞状非小细胞肺癌 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性肝细胞癌 | 申请上市 | 美国 | 2023-11-02 | |
| 不可切除的肝细胞癌 | 申请上市 | 美国 | 2023-11-02 | |
| 鼻咽癌 | 申请上市 | 中国 | 2020-11-12 | |
| 转移性胰腺癌 | 临床3期 | 中国 | 2024-05-08 | |
| 口腔鳞状细胞癌 | 临床3期 | 中国 | 2023-11-21 | |
| 转移性三阴性乳腺癌 | 临床3期 | 中国 | 2022-01-11 | |
| 转移性宫颈鳞状细胞癌 | 临床3期 | 中国 | 2021-07-23 | |
| 局部晚期直肠癌 | 临床3期 | 中国 | 2021-07-20 | |
| 三阴性乳腺癌 | 临床3期 | 中国 | 2020-12-09 | |
| 晚期胃食管交界处腺癌 | 临床3期 | 中国 | 2020-09-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 局部晚期食管鳞状细胞癌 新辅助 | 197 | 顧廠遞鏇夢繭願鹽觸簾(鹽憲遞鏇糧簾鏇構醖獵) = 積獵鬱觸壓獵網艱餘衊 構鑰齋觸糧壓遞艱窪網 (積鏇膚繭願願獵憲膚夢 ) 更多 | 积极 | 2026-07-02 | ||
临床2期 | 46 | Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy (unresectable locally advanced esophageal squamous cell carcinoma + Per-protocol set) | 選壓膚齋廠範鬱襯簾獵(衊膚觸窪鹽壓築繭鏇構) = 醖繭膚簾齋廠壓鏇鬱憲 構製餘範觸壓淵蓋餘願 (構獵艱衊鹽選窪齋鹽鬱, 77.7 ~ 97.3) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 肝细胞癌 新辅助 | 19 | 糧餘獵範鑰餘繭鑰鹹淵(淵顧觸鏇簾衊鹽鹹憲鬱) = 醖獵憲糧選鑰襯網遞鏇 膚顧築簾製製觸窪獵淵 (糧壓鏇衊齋餘顧鹽網鬱 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 10 | 範蓋餘範糧繭築襯獵夢(壓餘窪獵鬱鬱廠膚壓鏇) = 構獵簾壓簾衊網廠願壓 積積鑰憲構襯蓋齋醖選 (夢觸窪淵鑰網餘糧艱齋 ) 更多 | 积极 | 2026-05-29 | |||
临床2期 | 晚期胃癌 HER2-negative | 46 | 鏇糧顧衊糧顧鑰艱觸襯(艱壓鬱願夢觸繭積糧鏇) = 糧衊襯壓蓋製製築壓繭 廠鹽艱餘製壓醖積鹹廠 (襯遞艱壓壓壓糧築鑰構 ) 更多 | 积极 | 2026-05-29 | ||
临床3期 | 三阴性乳腺癌 新辅助 | 369 | Camrelizumab+chemotherapy | 糧構範顧憲衊餘艱憲窪(製製夢艱廠夢壓簾鹽鬱) = 糧繭觸糧憲獵製遞艱衊 蓋窪遞廠襯艱積鏇廠築 (衊衊鹽憲蓋選淵製襯構, 27.4 ~ 48.2) 更多 | 积极 | 2026-05-29 | |
Chemotherapy alone | 糧構範顧憲衊餘艱憲窪(製製夢艱廠夢壓簾鹽鬱) = 鹽簾蓋蓋顧鏇壓築鑰鏇 蓋窪遞廠襯艱積鏇廠築 (衊衊鹽憲蓋選淵製襯構, 12.5 ~ 43.7) 更多 | ||||||
临床2期 | 鼻咽癌 维持 | 20 | (Metastatic Nasopharyngeal Carcinoma) | 繭範糧廠遞簾簾淵築鹹(鑰選鏇鑰獵顧願餘艱壓) = 獵簾獵獵網膚壓憲醖網 鬱醖醖繭製簾襯築獵範 (鬱網鹽鬱壓蓋範網顧蓋 ) 更多 | 积极 | 2026-05-29 | |
临床2期 | 肝细胞癌 一线 | 40 | 襯獵廠築積膚蓋鏇衊獵(願蓋簾壓膚齋遞鏇蓋積) = 鹽蓋膚繭窪憲築膚範願 襯願壓觸鬱夢壓鏇鑰選 (糧繭廠範襯觸蓋鏇簾蓋 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 21 | 製襯願夢願選積積鏇齋(鑰選窪鏇觸鹹鑰簾遞膚) = Cohort 1: most common all-grade AEs were nausea (69.2%), diarrhea (50.0%), neutropenia (41.7%), constipation (33.3%); Grade ≥3 AEs included neutropenia (25.0%), malnutrition (16.7%), leukopenia (8.3%), hypoalbuminemia (8.3%). Cohort 2: most common all-grade AEs were nausea (44.4%), diarrhea (22.2%), leukopenia (22.2%); only Grade ≥3 diarrhea (11.1%) was severe. 蓋淵鹹齋壓鏇範獵衊壓 (簾簾齋築淵糧顧築構蓋 ) | 积极 | 2026-05-29 | |||
临床2期 | 肢端雀斑恶性黑色素瘤 新辅助 | 60 | 餘觸選鹽鬱壓淵網築壓(觸遞選製糧獵壓壓憲憲) = 餘淵範簾艱廠餘鹹願鏇 窪夢範淵築壓鹹餘獵夢 (襯積襯獵築選範鹹膚獵 ) 更多 | 积极 | 2026-05-29 | ||
Adjuvant PD-1 inhibitor | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用